ASND
Ascendis Pharma A/S · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow +3.3% ·
net new positions +8.3%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 106 | +15 | 28.56M | $7.62B | +25 | −10 |
| Q1 2026 | 92 | -6 | 28.38M | $6.48B | +8 | −14 |
| Q4 2025 | 96 | -1 | 34.58M | $7.37B | — | −1 |
| Q3 2025 | 15 | 0 | 10.69M | $2.13B | +1 | −1 |
| Q2 2025 | 12 | -2 | 9.16M | $1.58B | — | −2 |
| Q1 2025 | 12 | +1 | 5.48M | $853.40M | +1 | — |
| Q4 2024 | 11 | -2 | 5.30M | $729.95M | — | −2 |
| Q3 2024 | 12 | +1 | 6.24M | $930.97M | +2 | −1 |
| Q2 2024 | 11 | — | 7.02M | $958.03M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 2.26M | -1.2% | $351.64M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 1.13M | +25.6% | $175.37M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 1.13M | +25.6% | $175.37M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 587.76K | -16.5% | $91.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 587.76K | -16.5% | $91.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 587.76K | -16.5% | $91.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 587.76K | -16.5% | $91.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 587.76K | -16.5% | $91.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 587.76K | -16.5% | $91.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 587.76K | -16.5% | $91.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 569.15K | +13.0% | $88.71M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 327.40K | New | $51.03M | 0.1% | New | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 264.87K | -26.0% | $41.28M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Duquesne Family Office ✦ | 158.72K | -40.1% | $24.74M | 0.8% | ▼ Trim | 3 | SEC ↗ |
| 15 | State Street Global Advisors ✦ (passive) | 66.78K | -6.9% | $10.41M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Geode Capital Management ✦ (passive) | 57.85K | +1.4% | $9.02M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Marshall Wace ✦ | 22.29K | -80.5% | $3.47M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Marshall Wace ✦ | 22.29K | -80.5% | $3.47M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 20.53K | -46.0% | $3.20M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 20.53K | -46.0% | $3.20M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 18.76K | +71.9% | $2.92M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $51.03M | 0.1% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 8 holders, 7.94M shares, $34.76M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 1.10K sh @ 245.85 · $270,435
Director · 900 sh @ 246.91 · $222,219
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology